Table 1.
Summary of Published Cases of COVID‐19 in SCD
| Reference | Age (years)/Gender (M/F) if Known | Complications of SCD during COVID‐19 | Main treatment | Reported outcome |
|---|---|---|---|---|
| Beerkens et al 57 | 21/M | VOC, ACS | Red blood cell (RBC) exchange transfusion | Favorable |
| Nur et al 58 | 24/M | VOC, ACS | Oxygen and opioid therapy | Favorable |
| Nur et al 58 | 20/F | VOC | Opioid therapy | Favorable |
| De Luna et al 21 | 45/M | ACS | IV tocilizumab, RBC exchange transfusion | Favorable |
| Hussain et al 59 | 32/M | VOC,? ACS | RBC exchange transfusion, intubation, ICU | Favorable |
| Hussain et al 59 | 37/F | VOC | IV fluids and opioid | Favorable |
| Hussain et al 59 | 22/F | Suspected ACS | Ceftriaxone, IV opioid | Favorable |
| Hussain et al 59 | 41/M | VOC | IV fluids and opioid | Favorable |
| Odiѐvre et al 22 | 16/F | ACS and PE | Non‐invasive ventilation, RBC exchange transfusion, ICU | Favorable |
| a McCloskey et al 23 | 57/unknown | Extremely Unwell | Palliation | Fatal |
| a McCloskey et al (5 additional cases) 23 | Unknown range | VOC | Oxygen and analgesic therapy | Favorable |
Abbreviations: ACS, Acute Chest Syndrome; F, Female; ICU, Intensive Care Unit; IV, Intravenous; M, Male; PE, Pulmonary Embolism; VOC, Vaso‐Occlusive Crisis.
a
Limited information available, article is in press.